4 results about "Bacilli class" patented technology

Provided is a carbonate-containing granular material production method with which it is possible to produce a carbonate-containing granular material at a cost lower than when using conventional methods.　The present invention has a carbonation step for bringing, into contact with a carbonation-target granular material at a maximum temperature of higher than 0°C to lower than 100°C, either water, a carbonation accelerator, and at least one among a carbon dioxide-containing substance, a carbonate ion-containing water, and a hydrogen carbonate ion-containing water, or a carbonation accelerator and at least one among a carbon dioxide-containing water, a carbonate ion-containing water, and a hydrogen carbonate ion-containing water. The total amount of water brought into contact in the carbonation step is 1 mass% or more of the carbonation-target granular material. The carbonation accelerator contains bacteria. The bacteria are at least one selected from the genus Bacillus, the family Bacillaceae, the class Bacilli, the family Clostridiaceae, the family Micrococcaceae, the family Microbacteriaceae, or the family Comamonadaceae.

The present invention relates to a novel fusion polypeptide comprising a polypeptide having N-glycosidase activity fused to an antioxidant moiety wherein the polypeptide having N-glycosidase activity is a polypeptide from a bacterium belonging to the phylum of Acidobacteria, preferably belonging to the class of Acidobacteria. The invention also relates to nucleic acid molecules, vectors and host cells encoding the fusion polypeptides, as well as compositions and kits thereof. The invention also provides methods for purification and / or for production of the fusion polypeptides, as well as in vitro uses of the fusion polypeptides or nucleic acid molecules, vectors or host cells encoding the fusion polypeptides or compositions thereof.

The application discloses an intestinal microorganism marker for mesenchymal stromal cells treating Crohn's disease, a product and application thereof, and provides the intestinal microorganism marker, which comprises one or more of the following: order of erysipelotrichales, genus of faecalibacterium, family of erysipelotrichaceae, class of bacilli, order of lactobacillales, family of lactobacillaceae, genus of lactobacillus, phylum of firmicutes, family of muribaculaceae, order of bacteroidales, class of bacteroidia, phylum of bacteroidetes, class of clostridia, order of lachnospirales, family of lachnospiraceae, class of clostridia UCG-014 and order of oscillatolales. The content or abundance of the above marker can be detected to predict the curative effect of mesenchymal stromal cells treating Crohn's disease. The application further provides a method for constructing a curative effect prediction model based on the above marker, and obtains the curative effect prediction model. The application can realize the early prediction of the curative effect of mesenchymal stromal cells treating Crohn's disease, and has a good clinical application prospect.

The application relates to the technical field of medicines, and provides application of a composition of enterococcus and berberine or a salt thereof in preparation of medicines for preventing and / or treating phenylketonuria. Specifically, the enterococcus can significantly metabolize phenylalanine in an in-vitro culture medium system; the enterococcus belongs to the firmicutes, the bacilli class, the lactobacillus order and the enterococcus family. Meanwhile, the enterococcus and the berberine can be combined to significantly treat the phenylketonuria; the plasma phenylalanine of the phenylketonuria milk mouse can be reduced by 34.2% after 4 weeks of treatment, which indicates that the enterococcus and the berberine have an outstanding treatment effect in preventing and / or treating the phenylketonuria.